Replimune Group, Inc.
REPL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737953
In the last 90 days, Replimune Group, Inc. insiders filed 0 open-market purchases and 3 sales; 200 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:57 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 29, 2026 | May 22, 2025 | May 16, 2024 | May 18, 2023 | May 19, 2022 |
| Operating expenses | $319.9M | $261.6M | $234.8M | $177.1M | $118.3M |
| Research and development | $221.2M | $189.4M | $175.0M | $126.5M | $79.5M |
| Selling, general and administrative | $98.7M | $72.2M | $59.8M | $50.6M | $38.8M |
| Operating income | -$319.9M | -$261.6M | -$234.8M | -$177.1M | -$118.3M |
| Interest expense | $6.80M | $5.78M | $4.50M | $1.96M | $0 |
| Income tax | -$551.0K | $468.0K | $408.0K | $288.0K | $0 |
| Net income | -$313.9M | -$247.3M | -$215.8M | -$174.3M | -$118.0M |
| EPS, basic | $-3.38 | $-3.07 | $-3.24 | $-2.99 | $-2.26 |
| EPS, diluted | $-3.38 | $-3.07 | $-3.24 | $-2.99 | $-2.26 |
| Weighted shares, basic | 92.8M | 80.6M | 66.6M | 58.2M | 52.2M |
| Weighted shares, diluted | 92.8M | 80.6M | 66.6M | 58.2M | 52.2M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 29, 2026 | May 22, 2025 | May 16, 2024 | May 18, 2023 | May 19, 2022 |
| Cash and equivalents | $209.0M | $111.1M | $74.5M | $146.6M | $105.9M |
| Short-term investments | $59.9M | $372.7M | $346.2M | $436.8M | $289.7M |
| Total current assets | $279.1M | $495.9M | $433.7M | $592.6M | $404.0M |
| Property, plant and equipment | $13.0M | $13.7M | $10.5M | $7.48M | $7.93M |
| Total assets | $332.4M | $551.3M | $487.7M | $646.6M | $461.2M |
| Accounts payable | $6.67M | $12.5M | $2.58M | $5.36M | $3.73M |
| Total current liabilities | $58.2M | $62.4M | $40.4M | $33.8M | $20.8M |
| Long-term debt | $83.3M | $46.4M | $44.8M | $28.6M | – |
| Total liabilities | $166.2M | $135.5M | $113.2M | $91.3M | $50.0M |
| Shareholders' equity | $166.2M | $415.8M | $374.5M | $555.3M | $411.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 29, 2026 | May 22, 2025 | May 16, 2024 | May 18, 2023 | May 19, 2022 |
| Operating cash flow | -$280.3M | -$192.3M | -$185.5M | -$128.1M | -$82.2M |
| Capital expenditures | $4.22M | $6.69M | $5.66M | $2.27M | $2.34M |
| Free cash flow | -$284.6M | -$198.9M | -$191.1M | -$130.3M | -$84.5M |
| Depreciation and amortization | $3.33M | $3.50M | $2.65M | $2.45M | $2.15M |
| Stock-based compensation | $32.3M | $35.0M | $34.1M | $28.1M | $24.3M |
| Investing cash flow | $310.8M | -$23.8M | $97.2M | -$142.5M | -$1.81M |
| Financing cash flow | $66.3M | $252.4M | $16.3M | $311.3M | $6.60M |
| Net change in cash | $97.9M | $36.7M | -$72.1M | $40.6M | -$76.6M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 23, 2026 | 94.8M | +20.9% | SEC |
| Aug 11, 2026 | 94.2M | +20.7% | SEC |
| Jun 25, 2026 | 83.9M | +8.9% | SEC |
| Jan 30, 2026 | 82.6M | +7.2% | SEC |
| Nov 3, 2025 | 78.4M | +14.7% | SEC |
| Aug 4, 2025 | 78.1M | +14.2% | SEC |
| May 19, 2025 | 77.1M | +25.5% | SEC |
| Feb 7, 2025 | 77.0M | +25.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.